Brief: Nykode Says On-Track To Leverage Phase 2 Cervical Cancer Data
Sept 20 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS ANNOUNCES ADVANCES IN CLINICAL
PIPELINE AND
RESEARCH
* ON-TRACK TO LEVERAGE PROMISING PHASE 2 CERVICAL CANCER
DATA WITH
FDA CLEARANCE TO START POTENTIALLY REGISTRATIONAL TRIAL IN 2023
Source text for Eikon: ID:nObiDsDkRa
Further company coverage: NYKD.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026